Form **8937**

(December 2011) Department of the Treasury Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-2224

Part I Reporting Issuer		
1 Issuer's name		2 Issuer's employer identification number (EIN)
PDL BioPharma, Inc.		94-3023969
3 Name of contact for additional information	4 Telephone No. of contact	5 Email address of contact
Edward Imbrogno	775-832-8504	edward.imbrogno@pdl.com
6 Number and street (or P.O. box if mail is not delivered to street address) of contact		7 City, town, or post office, state, and Zip code of contact
922 Southwest Boulevard		Incline Village, NV 89451
8 Date of action	9 Classification and description	
May 21, 2020	Conversion Rate Adjustment on Conver	tible Debt
10 CUSIP number 11 Serial number	(s) 12 Ticker symbol	13 Account number(s)
69329YAJ3 69329YAG9		
	ch additional statements if needed. See ba	ack of form for additional questions.
14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for		
the action In accordance with the terms of its 2.75% Convertible Senior Notes due 2021 and 2024 (the "Notes"), PDL Biopharma, Inc.		
("PDL") adjusted the conversion rate of the Notes as a result of PDL's distribution of its stock in Evofem Biosciences, Inc. to its common		
stock holders. The conversion rate was increased from 262.2951 per Note to 316.5801 per Note on May 21, 2020.		
•		
The value of the conversion rate adjustment was calculated to be \$118.91 per Note.		
See separate Form 8937 for a discussion of PDL's distribution of Evofem Biosciences, Inc. to its common stock holders.		
oss soparato i sim ossi i si a alcoassion si i	DE O GIOGRADA DE L'OTOM DI DOCUMENTO DE L'OTOM	To No common stock notación
	6.5	
		3
15 Describe the quantitative effect of the orga	anizational action on the basis of the security in	the hands of a U.S. taxpayer as an adjustment per
share or as a percentage of old basis PDL does not expect the Note conversion rate adjustment to be treated for U.S. federal		
income tax purposes as a section 305(c) deemed distribution to holders of the Notes as the distribution of Evofem to its common stock		
holders was a section 331 liquidating distribution rather than a section 301 distribution. In addition, (1) no other distributions with respect		
to stock have been made in the prior 36 months, and (2) future distributions with respect to stock are intended to constitute liquidating		
distributions governed by section 331. Accordingly, holders of the Notes should not be treated as receiving a taxable dividend, and are not		
expected to have a basis adjustment in their Notes as a result of the Note conversion rate adjustment.		
	* 4	
· · · · · · · · · · · · · · · · · · ·	e	
,		
16 Describe the calculation of the change in I	pasis and the data that supports the calculation	, such as the market values of securities and the
		s a result of the Note conversion rate adjustment.
		Ų

Page 2

Form 8937 (Rev. 12-2011)